Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
September 17, 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
September 16, 2024 14:24 ET
|
Bernstein Liebhard LLP
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
September 13, 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
September 09, 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
September 09, 2024 16:12 ET
|
Bernstein Liebhard LLP
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2
September 09, 2024 07:00 ET
|
Evaxion Biotech
New pre-clinical data demonstrates that the novel EVX-B2 mRNA vaccine candidate triggers a targeted immune response The specific immune response leads to the elimination of the gonorrhea bacteriaThe...
ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRNA
September 05, 2024 12:04 ET
|
The Rosen Law Firm PA
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and...
BioNTech präsentiert auf dem ESMO-Kongress 2024 klinische Daten-Updates aus dem mRNA und immunmodulatorischen Onkologie-Portfolio
September 05, 2024 07:15 ET
|
BioNTech SE
MAINZ, Deutschland, 05. September 2024 – BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird auf dem diesjährigen Kongress der European Society for Molecular Oncology („ESMO“), der vom...
BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
September 05, 2024 07:15 ET
|
BioNTech SE
MAINZ, Germany, September 05, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, PDD Holdings, Extreme Networks, and Sprinklr and Encourages Investors to Contact the Firm
September 03, 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...